Alfredo Carlos Simões Dornellas de Barros
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alfredo Carlos Simões Dornellas de Barros has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Felipe Eduardo Martins de Andrade
Hospital Sírio-Libanês, São Paulo, SP, Brazil
6 shared publications - Ruffo Freitas-Junior
Universidade Federal de Goiás
4 shared publications - Cicero Urban
Hospital Nossa Senhora das Graças,Curitiba,Brazil, Brazil
2 shared publications - Gil Facina
Universidade Federal de São Paulo
2 shared publications - Giuliano Tosello
Universidade do Oeste Paulista
2 shared publications - Guilherme Garcia Novita
Oncoclínicas, São Paulo, Brazil
2 shared publications
Latest Publications
- Open Access
- 5 June 2026
- Published by MDPI AG in Preprints.org
MammaPrint™ Genetic Signature in the Brazilian Population, Analysis of Results and Clinical Outcomes (AGEMA-BRA) – Real World Study
Purpose: The MammaPrint™ (MP) 70-gene signature, identifies hormone receptor-positive (HR+), HER2-negative breast cancer patients with low genomic risk who are candidates for de-escalation of the systemic therapies employed. Knowing that MP was validated in an exclusively European cohort and understanding the heterogeneity of breast tumors in different populations, we proposed a study to analyze MP performance in the Brazilian population. Methods: Retrospective, prognostic evaluation, real-world cohort study of HR+, HER2- breast cancer patients who underwent MP in Brazil from January 2016 to December 2020 (AGEMA-BRA). Results: Of the 953 patients with high clinical risk, 407 (42.7%) had high genomic risk, and 546 (57.3%) had low genomic risk to MP. In the analysis of epidemiological, clinical, and anato-mopathological data correlating high and low risk to MP, and among the subgroups with low-risk, ultra-low risk, high-risk 1 and high-risk 2, only the histological grade showed statistical significance. Distant metastasis-free survival (DMFS) was 97.8% and overall survival (OS) was 99.8% with a mean follow-up of 40.8 months, with no difference between high and low genomic risk. Conclusions: Applying the MP signature in the AGEMA-BRA cohort enabled greater chemotherapy de-escalation with better DMFS than observed in the MINDACT pivotal study. Equivalent DMFS and OS results between high and low genomic risk carriers demonstrate the appropriate selection of patients by MP to receive or not receive adjuvant chemotherapy. These data make it possible to validate the performance of the signature in the Brazilian population and confirm the importance of testing it in different populations.
- 5 June 2026
- Published by MDPI AG in Preprints.org
Open AccessMammaPrint™ Genetic Signature in the Brazilian Population, Analysis of Results and Clinical Outcomes (AGEMA-BRA) – Real World Study
Purpose: The MammaPrint™ (MP) 70-gene signature, identifies hormone receptor-positive (HR+), HER2-negative breast cancer patients with low genomic risk who are candidates for de-escalation of the systemic therapies employed. Knowing that MP was validated in an exclusively European cohort and understanding the heterogeneity of breast tumors in different populations, we proposed a study to analyze MP performance in the Brazilian population. Methods: Retrospective, prognostic evaluation, real-world cohort study of HR+, HER2- breast cancer patients who underwent MP in Brazil from January 2016 to December 2020 (AGEMA-BRA). Results: Of the 953 patients with high clinical risk, 407 (42.7%) had high genomic risk, and 546 (57.3%) had low genomic risk to MP. In the analysis of epidemiological, clinical, and anato-mopathological data correlating high and low risk to MP, and among the subgroups with low-risk, ultra-low risk, high-risk 1 and high-risk 2, only the histological grade showed statistical significance. Distant metastasis-free survival (DMFS) was 97.8% and overall survival (OS) was 99.8% with a mean follow-up of 40.8 months, with no difference between high and low genomic risk. Conclusions: Applying the MP signature in the AGEMA-BRA cohort enabled greater chemotherapy de-escalation with better DMFS than observed in the MINDACT pivotal study. Equivalent DMFS and OS results between high and low genomic risk carriers demonstrate the appropriate selection of patients by MP to receive or not receive adjuvant chemotherapy. These data make it possible to validate the performance of the signature in the Brazilian population and confirm the importance of testing it in different populations.
- Open Access
Thirty-five years of publications: from “Revista Brasileira de Mastologia” to “Mastology”
- 1 July 2022
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 18 (3) , 229-234
Association Between GATA3 and Histopathological and Immunohistochemical Parameters in Early-Infiltrating Breast Carcinomas
This study evaluated the frequency of GATA-binding protein 3 (GATA3) expression in early breast cancer and its relationship with histopathological and immunohistochemical parameters. GATA3 was analysed by immunohistochemistry in histological sections of tumors from 105 female patients, with histological diagnosis of invasive breast carcinoma (BC), at clinical stages I, II and IIIA, who underwent primary surgical treatment. GATA3 nuclear expression was determined as the percentage of positive tumor cells and further categorized as high (positive expression in more than 95% of cells) or non-high (negative or low positive expression in up to 95% of tumor cells). GATA3 expression was analysed according to the patient age, tumor and node pathological stage, histological type, histological and nuclear grade, lymphovascular invasion, and estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), human epidermal growth factor 2 (HER2) status, and Ki-67 expression. GATA3 expression was positive in 103 cases (98.1%). High expression was significantly associated with low histological and nuclear grade, positive hormonal receptors, and less proliferative activity based on Ki-67 expression. A prominent feature was that 94.7% of the ER-positive/HER2-negative cases presented high-GATA3 expression, as 94.0% of the tumors showing high-GATA3 were ER-positive. In ER-negative/HER2-positive or ER-negative/HER2- negative, high-GATA3 was present in 25% while 75% were non-high-GATA3 compared with ER-positive/HER2- negative (4.1%) and ER-positive/HER2-positive (20%). Proliferative activity in triple-negative breast cancer tended to be higher among tumors with low-GATA3, irrespective of AR expression. In the group of ER-positive/HER2-negative tumors only three cases were low-GATA3 (85% and 80%), both with high proliferative activity. High GATA3 expression is associated with favorable histopathologic and immunohistochemical BC prognostic factors.
- 1 July 2022
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 18 (3) , 229-234
Association Between GATA3 and Histopathological and Immunohistochemical Parameters in Early-Infiltrating Breast Carcinomas
This study evaluated the frequency of GATA-binding protein 3 (GATA3) expression in early breast cancer and its relationship with histopathological and immunohistochemical parameters. GATA3 was analysed by immunohistochemistry in histological sections of tumors from 105 female patients, with histological diagnosis of invasive breast carcinoma (BC), at clinical stages I, II and IIIA, who underwent primary surgical treatment. GATA3 nuclear expression was determined as the percentage of positive tumor cells and further categorized as high (positive expression in more than 95% of cells) or non-high (negative or low positive expression in up to 95% of tumor cells). GATA3 expression was analysed according to the patient age, tumor and node pathological stage, histological type, histological and nuclear grade, lymphovascular invasion, and estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), human epidermal growth factor 2 (HER2) status, and Ki-67 expression. GATA3 expression was positive in 103 cases (98.1%). High expression was significantly associated with low histological and nuclear grade, positive hormonal receptors, and less proliferative activity based on Ki-67 expression. A prominent feature was that 94.7% of the ER-positive/HER2-negative cases presented high-GATA3 expression, as 94.0% of the tumors showing high-GATA3 were ER-positive. In ER-negative/HER2-positive or ER-negative/HER2- negative, high-GATA3 was present in 25% while 75% were non-high-GATA3 compared with ER-positive/HER2- negative (4.1%) and ER-positive/HER2-positive (20%). Proliferative activity in triple-negative breast cancer tended to be higher among tumors with low-GATA3, irrespective of AR expression. In the group of ER-positive/HER2-negative tumors only three cases were low-GATA3 (85% and 80%), both with high proliferative activity. High GATA3 expression is associated with favorable histopathologic and immunohistochemical BC prognostic factors.
Clinic, pathologic and molecular landscapes in ultra-young women with breast cancer in the State of São Paulo: a real-world study
Introduction: Breast cancer (BC) centers are increasingly attending “ultra-young” women (UYW) patients (≤ 30 years), who usually present aggressive tumors and face specific problems. Objectives: We aimed to examine a multicentric casuistic view, addressing clinicopathological and molecular characteristics of BC, as well as therapeutic measures and oncological outcomes. Methods: A retrospective multicentric observational study of UYW with infiltrating BC was carried out. The patients were treated between the period from January 1991 to December 2019. Clinical, epidemiological, morphological, molecular, therapeutic and outcomes data were collected from the charts. Results: A total of 293 patients were followed for a average period of 34.5 months. Nulliparity was referred by 204 women (75.5%), of whom 81 (37.1%) were overweight or obese. Positive family history in first-degree relatives was verified in 25 patients (10.1%). Only 30 patients underwent genetic tests, which revealed inherited pathogenic mutations in 12 of them (37.5%). Thirty-two (32) cases were classified as T1 at diagnosis (10.9%), while “De novo” stage IV was found in 29 patients (9.8%). Mastectomy was performed in 175 women (70.2%), quadrantectomy in 46 women (18.4%), and mammary adenectomies in 28 women (11.2%), of which 149 cases were reported after neoadjuvant chemotherapy (56.0%). A total of 111 patients had at least one positive lymph node (47.4%). The rate of patients with estrogen receptor-negative was 32.7% and the rate of patients with Human Epidermal Growth Factor Receptor 2-positive (HER2-positive) was 25%. The frequency of Luminal A neoplasias was 16.6%, Luminal B/HER2- was 35.9%, Luminal B/HER2+ was 15.1%, HER2 overexpressed was 9.3%, and Basal was 22.9%. Taking into account the outcomes, 173 patients were alive without disease (65.7%); 23 patients were alive with any form of recurrence (8.7%); and 67 patients (25.4%) evolved to BC deaths. Conclusions: It was concluded that UYW with BC are commonly diagnosed at advanced stages, present adverse morphological and molecular parameters, and have unfavorable prognosis.
Clinic, pathologic and molecular landscapes in ultra-young women with breast cancer in the State of São Paulo: a real-world study
Introduction: Breast cancer (BC) centers are increasingly attending “ultra-young” women (UYW) patients (≤ 30 years), who usually present aggressive tumors and face specific problems. Objectives: We aimed to examine a multicentric casuistic view, addressing clinicopathological and molecular characteristics of BC, as well as therapeutic measures and oncological outcomes. Methods: A retrospective multicentric observational study of UYW with infiltrating BC was carried out. The patients were treated between the period from January 1991 to December 2019. Clinical, epidemiological, morphological, molecular, therapeutic and outcomes data were collected from the charts. Results: A total of 293 patients were followed for a average period of 34.5 months. Nulliparity was referred by 204 women (75.5%), of whom 81 (37.1%) were overweight or obese. Positive family history in first-degree relatives was verified in 25 patients (10.1%). Only 30 patients underwent genetic tests, which revealed inherited pathogenic mutations in 12 of them (37.5%). Thirty-two (32) cases were classified as T1 at diagnosis (10.9%), while “De novo” stage IV was found in 29 patients (9.8%). Mastectomy was performed in 175 women (70.2%), quadrantectomy in 46 women (18.4%), and mammary adenectomies in 28 women (11.2%), of which 149 cases were reported after neoadjuvant chemotherapy (56.0%). A total of 111 patients had at least one positive lymph node (47.4%). The rate of patients with estrogen receptor-negative was 32.7% and the rate of patients with Human Epidermal Growth Factor Receptor 2-positive (HER2-positive) was 25%. The frequency of Luminal A neoplasias was 16.6%, Luminal B/HER2- was 35.9%, Luminal B/HER2+ was 15.1%, HER2 overexpressed was 9.3%, and Basal was 22.9%. Taking into account the outcomes, 173 patients were alive without disease (65.7%); 23 patients were alive with any form of recurrence (8.7%); and 67 patients (25.4%) evolved to BC deaths. Conclusions: It was concluded that UYW with BC are commonly diagnosed at advanced stages, present adverse morphological and molecular parameters, and have unfavorable prognosis.
- Open Access
- 31 October 2019
- Published by FapUNIFESP (SciELO) in Sao Paulo Medical Journal
- Vol. 137 (4) , 336-342
Mammary adenectomy followed by immediate reconstruction for treatment of patients with early-infiltrating breast carcinoma: a cohort study
KEY WORDS: Breast neoplasms; Mastectomy; Prognosis; Esthetics
- 31 October 2019
- Published by FapUNIFESP (SciELO) in Sao Paulo Medical Journal
- Vol. 137 (4) , 336-342
Open AccessMammary adenectomy followed by immediate reconstruction for treatment of patients with early-infiltrating breast carcinoma: a cohort study
KEY WORDS: Breast neoplasms; Mastectomy; Prognosis; Esthetics
- 1 July 2018
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 44 (7) , 1119-1120
Reply to: Mastectomy skin flap thickness
- 1 July 2018
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 44 (7) , 1119-1120
Reply to: Mastectomy skin flap thickness
- Open Access
- 1 April 2018
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 51 (2) , 247-248
Cat scratch disease presenting as axillary lymphadenopathy and a palpable benign mammary nodule mimicking a carcinoma
We present a case involving a 74-year-old woman with cat scratch disease characterized by an enlarged and hard axillary lymph node as well as a palpable breast nodule mimicking a carcinoma. The lymph node and the breast nodule were excised. The pathologic examinations revealed granulomatous lymphadenitis with gram-negative bacilli and an intraductal papilloma. Antibiotic therapy (azithromycin) was prescribed and the patient’s clinical evolution was excellent.
- 1 April 2018
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 51 (2) , 247-248
Open AccessCat scratch disease presenting as axillary lymphadenopathy and a palpable benign mammary nodule mimicking a carcinoma
We present a case involving a 74-year-old woman with cat scratch disease characterized by an enlarged and hard axillary lymph node as well as a palpable breast nodule mimicking a carcinoma. The lymph node and the breast nodule were excised. The pathologic examinations revealed granulomatous lymphadenitis with gram-negative bacilli and an intraductal papilloma. Antibiotic therapy (azithromycin) was prescribed and the patient’s clinical evolution was excellent.
- 1 November 2017
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 43 (11) , 2036-2043
Multidisciplinary international survey of post-operative radiation therapy practices after nipple-sparing or skin-sparing mastectomy
- 1 November 2017
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 43 (11) , 2036-2043
Multidisciplinary international survey of post-operative radiation therapy practices after nipple-sparing or skin-sparing mastectomy
- Open Access
- 30 April 2016
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 14 (1) , 135
Surgical anatomy of the internal thoracic lymph nodes in fresh human cadavers: basis for sentinel node biopsy
While the optimal management of early breast cancer patients with sentinel lymph node (SLN) involvement mapped in the internal thoracic chain is still debated, biopsy may be performed when surgeons select patients who are most likely to benefit. The aim of this study is to examine anatomical aspects of internal thoracic nodes (ITNs) to orientate SLN biopsy in the parasternal area. This study was based on dissections of 29 female cadavers. The parameters analyzed were the number of intercostal spaces (ICSs) containing at least one ITN, mean number of nodes in each ICS, position of the ITNs in relation to the internal thoracic artery (ITA), number of retrocostal spaces (RCSs) containing at least one ITN, and mean number of nodes in each RCS. The ICS that was most likely to have at least one ITN was the third, with 86.2 % in the right side and 75.8 % in the left side. In the second ICS, the rates were 69.2 and 73.6 %, and in the fourth, the rates were 48.1 and 33.3 %. In the third ICS, on both sides, the mean number of ITNs was the highest (1.2). A tendency of the nodes to be laterally located in the second ICS and medially located in the downward dissection was observed. Most of the RCSs did not present any nodes. This study indicates that most of the second and third ICSs presented at least one ITN, and the mean number of nodes in the third space was greater. There is a tendency to find nodes medial to the artery downwards from the second to the fourth ICS. ITNs are generally located in ICSs, and the majority of RCSs did not contain any nodes.
- 30 April 2016
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 14 (1) , 135
Open AccessSurgical anatomy of the internal thoracic lymph nodes in fresh human cadavers: basis for sentinel node biopsy
While the optimal management of early breast cancer patients with sentinel lymph node (SLN) involvement mapped in the internal thoracic chain is still debated, biopsy may be performed when surgeons select patients who are most likely to benefit. The aim of this study is to examine anatomical aspects of internal thoracic nodes (ITNs) to orientate SLN biopsy in the parasternal area. This study was based on dissections of 29 female cadavers. The parameters analyzed were the number of intercostal spaces (ICSs) containing at least one ITN, mean number of nodes in each ICS, position of the ITNs in relation to the internal thoracic artery (ITA), number of retrocostal spaces (RCSs) containing at least one ITN, and mean number of nodes in each RCS. The ICS that was most likely to have at least one ITN was the third, with 86.2 % in the right side and 75.8 % in the left side. In the second ICS, the rates were 69.2 and 73.6 %, and in the fourth, the rates were 48.1 and 33.3 %. In the third ICS, on both sides, the mean number of ITNs was the highest (1.2). A tendency of the nodes to be laterally located in the second ICS and medially located in the downward dissection was observed. Most of the RCSs did not present any nodes. This study indicates that most of the second and third ICSs presented at least one ITN, and the mean number of nodes in the third space was greater. There is a tendency to find nodes medial to the artery downwards from the second to the fourth ICS. ITNs are generally located in ICSs, and the majority of RCSs did not contain any nodes.
- Open Access
- 17 December 2014
- Published by Hindawi Limited in International Journal of Breast Cancer
- Vol. 2014, 1-8
Intraoperative Full-Dose of Partial Breast Irradiation with Electrons Delivered by Standard Linear Accelerators for Early Breast Cancer
Purpose. To assess feasibility, efficacy, toxicity, and cosmetic results of intraoperative radiotherapy (IORT) with electrons delivered by standard linear accelerators (Linacs) during breast conserving surgeries for early infiltrating breast cancer (BC) treatment.Materials and Methods. A total of 152 patients with invasive ductal carcinoma ( cm) at low risk for local relapses were treated. All had unicentric lesions by imaging methods and negative sentinel node. After a wide local excision, 21 Gy were delivered on the parenchyma target volume with electron beams. Local recurrences (LR), survival, toxicity, and cosmetic outcomes were analyzed.Results. The median age was 58.3 years (range 40–85); median follow-up was 50.7 months (range 12–101.5). There were 5 cases with LR, 2 cases with distant metastases, and 2 cases with deaths related to BC. The cumulative incidence rates of LR, distant metastases, and BC death were 3.2%, 1.5%, and 1.5%, respectively. Complications were rare, and the cosmetic results were excellent or good in most of the patients.Conclusions. IORT with electrons delivered by standard Linacs is feasible, efficient, and well tolerated and seems to be beneficial for selected patients with early infiltrating BC.- 17 December 2014
- Published by Hindawi Limited in International Journal of Breast Cancer
- Vol. 2014, 1-8
Open AccessIntraoperative Full-Dose of Partial Breast Irradiation with Electrons Delivered by Standard Linear Accelerators for Early Breast Cancer
Purpose. To assess feasibility, efficacy, toxicity, and cosmetic results of intraoperative radiotherapy (IORT) with electrons delivered by standard linear accelerators (Linacs) during breast conserving surgeries for early infiltrating breast cancer (BC) treatment.Materials and Methods. A total of 152 patients with invasive ductal carcinoma ( cm) at low risk for local relapses were treated. All had unicentric lesions by imaging methods and negative sentinel node. After a wide local excision, 21 Gy were delivered on the parenchyma target volume with electron beams. Local recurrences (LR), survival, toxicity, and cosmetic outcomes were analyzed.Results. The median age was 58.3 years (range 40–85); median follow-up was 50.7 months (range 12–101.5). There were 5 cases with LR, 2 cases with distant metastases, and 2 cases with deaths related to BC. The cumulative incidence rates of LR, distant metastases, and BC death were 3.2%, 1.5%, and 1.5%, respectively. Complications were rare, and the cosmetic results were excellent or good in most of the patients.Conclusions. IORT with electrons delivered by standard Linacs is feasible, efficient, and well tolerated and seems to be beneficial for selected patients with early infiltrating BC.